Biotech Values

[DewDiligence]

>That also would favor NFLD and Polyheme for trauma patients and some elective surgeries...<

The tradeoff is a little different when you are talking about whole blood as opposed to a single plasma protein. That’s why I see concerns about the safety of the blood supply helping companies like GTCB and ZGEN to a greater degree than NFLD. But it could be a significant boost for NFLD too, especially if the kinds of incidents described in my prior post continue.